A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

Must have received: systemic therapy — metastatic

Disease progression on one prior line of therapy for metastatic disease. Patients with previously untreated advanced unresectable or metastatic disease may be included if disease progressed or recurred during neoadjuvant or adjuvant therapy or within 6 months of completion of those treatments.

Cannot have received: VEGFR inhibitor (ramucirumab)

Received prior therapy with ramucirumab at any time

Cannot have received: taxane (paclitaxel, docetaxel)

Exception: within 6 month of study enrollment

Received paclitaxel or docetaxel-based therapy within 6 month of study enrollment

Cannot have received: anti-PD-1 therapy

Exception: prior grade >3 immune related adverse event due to anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA4 therapy at any time

Had a prior grade >3 immune related adverse event due to anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA4 therapy at any time